Monthly Prescribing Reference14h
Cord Blood Stem Cell Therapy RegeneCyte Gets FDA Approval
The BLA approval is supported by data from the COBLT study, FDA dockets and public information, and from a RegeneCyte observational database.
Monthly Prescribing Reference14h
Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before Delivery
Maternal vaccination two to three or three to four weeks before delivery linked to lower cord:maternal transfer ratios versus at least five weeks ...
Monthly Prescribing Reference16h
Consensus Statement Issued for Low-Dose Oral Minoxidil for Hair Loss
Seventy-six items achieved consensus, including indications for LDOM versus topical minoxidil, dosing for adults and teens, contraindications ...
Monthly Prescribing Reference14h
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...
Monthly Prescribing Reference14h
US Overweight, Obesity Rates Set to Continue Increasing to 2050
(HealthDay News) — Based on the current trajectory, overweight and obesity will continue increasing in the United States up to 2050, according to a study published online Nov. 14 in The Lancet.
Monthly Prescribing Reference16h
Miplyffa Now Available for Niemann-Pick Disease Type C
Miplyffa was approved in September 2024 based on data from a clinical trial that showed arimoclomol plus miglustat slowed NPC disease progression.